ProPhase Labs, Inc. (NASDAQ:PRPH) Director Jason Michael Barr sold 4,379 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $10,071.70. Following the transaction, the director now owns 7,721 shares in the company, valued at approximately $17,758.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) opened at 2.14 on Tuesday. The firm has a market cap of $34.60 million, a price-to-earnings ratio of 0.89 and a beta of 0.02. ProPhase Labs, Inc. has a 1-year low of $1.78 and a 1-year high of $2.45. The company has a 50 day moving average of $2.23 and a 200 day moving average of $2.08.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Friday, August 11th. The company reported ($0.09) EPS for the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%. The business had revenue of $1.91 million for the quarter.

ProPhase Labs announced that its board has initiated a stock repurchase program on Tuesday, August 15th that authorizes the company to buyback 4,000,000 outstanding shares. This buyback authorization authorizes the company to buy shares of its stock through a tender offer. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/03/prophase-labs-inc-prph-director-jason-michael-barr-sells-4379-shares.html.

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Receive News & Stock Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related stocks with our FREE daily email newsletter.